Drug Development Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X

Fampridine-SR – Treatment for Multiple Sclerosis

Drug (Brand/Generic)

Fampridine-SR (4-aminopyridine)

Company/Licensee

Acorda Therapeutics

Therapy Class

Potassium channel blocker

Product Description

Selective neuronal potassium (K+) channel blocker

Current Indication

Treatment of MS

Market Sector

CNS

Development Status

Approved in US. Marketing authorisation application submitted in EU and new drug application submitted in Canada
Expand

Go Top